This report summarizes the key takeaways from a recent round table with a panel of experts representing early stage biotech, pharmaceutical, supply chain management and logistics companies:

• Orchestrating cell and gene therapies requires bespoke solutions in terms of storage, transportation, timelines, temperature control, and servicer flexibility
• In these incredibly complex supply chains, forming and orchestrating partnerships is a necessity
• In order for logistics vendors to form partnerships with cell and gene therapy manufacturers it is important to understand each company's unique requirements
• Scalability of logistics solutions is also an important consideration